Lymphoma 'vaccine' given Orphan Drug Designation

fda-logo.jpg

On the basis of some encouraging Phase III clinical trial results published last year, the US Food and Drug Administration has granted Orphan Drug Designation to BiovaxID, the so-called 'personalized lymphoma vaccine' from Biovest.

The designation is a boon for Biovest, granting them market exclusivity for seven years following approval, reduced filing fees, tax credits, and possible grant funding for R & D.

Clinical trials by Biovest of BiovaxID have focused primarily on subjects with follicular lymphoma, but the company believes their targeted, customized therapy could be effective against other B-cell cancers, including some lymphomas, leukemias, and even multiple myeloma.

By Ross Bonander

LymphomaInfo Social